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The G-protein coupled receptors (GPCRs) superfamily comprise similar proteins arranged into families or
classes thus making it one of the largest in the mammalian genome. GPCRs take part in many vital
physiological functions making them targets for numerous novel drugs. GPCRs share some distinctive
features, such as the seven transmembrane domains, they also differ in the number of conserved
residues in their transmembrane domain. Here we provide an introductory and accessible review
detailing the computational advances in GPCR pharmacology and drug discovery. An overview is
provided on family A-C GPCRs; their structural differences, GPCR signalling, allosteric binding and
cooperativity. The dielectric constant (relative permittivity) of proteins is also discussed in the context of
site-specific environmental effects.Background
The G-protein coupled receptor (GPCR) superfamily consists of
structurally similar proteins arranged into families (classes),
and is one of the most abundant protein classes in the
mammalian genome.1–5 GPCRs undertake a plethora of essen-
tial physiological functions and are targets for numerous novel
drugs.4,5 Their ligands are structurally heterogenous, including
natural odorants, nucleotides, amines, peptides, proteins, and
lipids.4 The conserved structure of GPCRs consists of seven
TMD of approximately 25–35 successive amino acid residues
that express moderately high levels of hydrophobicity4 and are
characterised by a-helices which span the plasma membrane.4
The primary function of GPCRs is the transduction of extra-
cellular stimuli into intracellular signals.2 Currently, approxi-
mately thirty to forty percent of marketed pharmaceuticals
target GPCRs.1,6–10 Hence, there is enormous potential for the
development of new drugs targeting these receptors.3 Examples
of drugs targeting GPCRs include histamine receptor blockers,
opioid agonists, b-blockers and angiotensin receptor blockers.5
Computational biology methods are currently being employed
to understand GPCRs as such drug targets.6,11,12 Breakthroughs
in GPCR crystallography has facilitated novel discovery throughre St, Nottingham NG1 4FQ, UK. E-mail:
neering Centre, University of Ulster,
0QB, Northern Ireland, UK
ster, LE1 9BH, UK
h, Claverton Down, Bath, BA1 7AY, UK
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f Chemistry 2020virtual screening as well as better off-target rationalisation.6
Recently, the Tikhonova group developed a computational
protocol which combines concepts from statistical mechanics
and cheminformatics to explore the exibility of the bioamine
receptors as well as to identify the geometrical and physico-
chemical properties which characterise the conformational
space of the bioamine family.13 Multiple-microsecond timescale
molecular dynamics (MD) simulations have been used in
capturing the process of several drugs binding to b1- and b2-
adrenergic receptors.14 Molecular docking is one of the most
commonly used methods in GPCR structure-based drug design
(SBDD).14 Esguerra et al. developed GPCR-ModSim, a web-based
portal designed specically for the homology modelling and
MD simulation of GPCRs.15
It was historically assumed that GPCRs exist in two confor-
mations: active and inactive.16–18 The long-established extended
ternary-complex model of GPCR-driven signalling was based on
this concept.16,19,20 This model suggested that the active GPCR
conformation opted for by G-protein-coupled receptor kinases
(GRKs), arrestins and G proteins is uniform.16 Nevertheless,
biophysical investigations with a rened uorescent-labelled
b2-adrenergic receptor (b2AR) demonstrated that a receptor
can exist in numerous conformations and that the conforma-
tional equilibrium is inuenced both by the bound ligand and
the proximity to the related G protein.16
The human genome alone contains approximately 800
GPCRs making it the largest family of membrane proteins.5,21
GPCRs have been classied based on structural and physio-
logical features.4 Some systems of classication have grouped
these based on location of the ligand binding pocket, while


































































































View Article Onlineproperties.4,22 The A–F classication system was the rst system
of classication to be introduced.23 This was rst introduced in
1994 as A–F, and O for the (now obsolete) GCRDb database by
Kolakowski.23 The defunct GCRDb system was further devel-
oped, leading to the GPCRDB24,25 database by Horn et al. with
the rhodopsin family (class A) being the largest and consisting
of four main groups: a, b, g, and d, and 13 sub-branches.4,23,24 All
GPCRs comprise of seven TMD helices (Fig. 1), alongside an
eight helix and a palmitoylated cysteine at the C terminal tail.26
The diversity of GPCRs has resulted in a perceived difficulty
in developing a comprehensive classication system.5 The A–F
system orders the GPCRs into six classications on the basis of
their sequence homology and functional similarity, namely:
family A (rhodopsin-like receptors), family B (secretin receptor
family), family C (metabotropic glutamate receptors), family D
(parasitic mating pheromone receptors), family E (cyclic AMP
receptors) and family F (frizzled and smoothened receptors).5
Based on phylogenetic studies, human GPCRs have been clas-
sied under a system called “GRAFS”, this system comprises of
ve main families namely; glutamate (G), rhodopsin (R),
adhesion (A), frizzled/taste2 (F), and secretin (S).4,21,26 The major
difference between the two systems concerns the additional
division of family B into the adhesion and secretin families
within GRAFS.26 This division was based on early ndings
describing a distinctive evolutionary history between both
families.26Family A (rhodopsin-like receptors)
The rhodopsin receptor family (RRF) is the largest of the GPCR
families, comprising of approximately 680 members, and
accounts for 80% of receptors in humans.4,28 The RRF is clas-
sied into four groups (a, b, g, d) and 13 main subdivisions,4,29
and it has numerous characteristics which indicate a common
ancestry.4,29 These characteristics include the DRY motifFig. 1 A schematic representation of a GPCR showing the transmembran
loops (generated using GPCRDB Tools, https://gpcrdb.org/).27
36338 | RSC Adv., 2020, 10, 36337–36348situated at the border between TM3 and intracellular loop (IL) 2
and NSxxNPxxY motif in TM7 (Fig. 2).4,29 The N-terminal region
of the family A GPCR receptors are situated extracellularly,29,30
while the C-terminal is located within the cytoplasm (Fig. 3).29,30
The ligand binding site is located within the extracellular region
of the TMD bundle.29
According to Palczewski, the arrangement of the seven TMD
helices which vary in length from 20 to 30 residues is respon-
sible for the overall elliptic, cylindrical shape of rhodopsin
(Fig. 3).30 The family A GPCRs vary greatly when their ligand
preference and primary structure are considered.31 However,
there is homogeneity in the N-termini of family A GPCRs, but
heterogeneity within the TMD regions.31 However, some of the
family A GPCRs share specic sequence motifs within the TMD
region.31
Palczewski reported the dimensions of rhodopsin as an
ellipsoid of approximately 35  48  75 Å, with the long axis
perpendicular to the membrane in the standard view.30 The
surface area of the section protruding from the membrane is
approximately 1200 Å2, with cytoplasmic projection being larger
in surface area and volume than the extracellular surface
(Fig. 2b).30 The TMD helices of rhodopsin are irregularly shaped
due to the conformational changes associated with the Gly–Pro
residues; they also incline at several angles in correspondence
to the anticipated membrane surface.32 Teller et al. reported
that helix 1 tilted from the membrane plane at 25 and contains
a 12 kink within it as a result of Pro53 residues being present.32
Helix 2 kinked at an angle of 30 around Gly89 and Gly90 and
the most signicant bend being at Helix 6 at angle of 36 due to
the presence of Pro267.32Family B (secretin receptor family)
The family B GPCRs form a small group, and with an extracel-
lular hormone-binding site, they bind to large peptides.31 Thee domains, N-terminus, C-terminus, the intracellular and extracellular
This journal is © The Royal Society of Chemistry 2020
Fig. 2 Schematic diagram showing the structure of family A GPCRs generated using ClustalW.31 Reprintedwith permission from Springer Nature:
Springer Nature, Nature Reviews Drug Discovery, Structural diversity of G protein-coupled receptors and significance for drug discovery, M. C.
Lagerström and H. B. Schiöth, Copyright (2008). The upper section of shows the differences in the secondary structure of the N termini of the
family A receptors.31 The scissor image indicates the cleavage site of the protease activated receptors whilst in the lower part of the image, the
schematic TMD regions show the consensus of an alignment generated using ClustalW 1.82.31 In addition, the area circled in red describes the
elliptical orientation.31 Residues conserved in all eight sequences are displayed as circles in which conserved aromatic residues are shown in


































































































View Article Onlinefamily name “secretin” derives from the secretin receptor,
which was the rst to be cloned in this family.3 In 1975, Sasaki
et al.33 solved the rst X-ray crystal structure of glucagon,
a family B GPCR.34 The family corresponds to group B of the A–F
system of classication,3 and comprises 15 members including:
vasoactive intestinal peptide receptors (vIPR1, vIPR2), glucagon-
like peptide receptors (GLP1R, GLP2R), adenylate cyclase acti-
vating polypeptide receptor (PAC1/ADCYAP1R1), growth-
hormone-releasing hormone receptor (GHRHR), calcitonin
and calcitonin-like receptors (CALCR, CALCRL), gastric inhibi-
tory polypeptide receptor (GIPR), secretin receptor (SCTR),
corticotropin-releasing hormone receptors (CRHR1, CRHR2),
glucagon receptor (GCGR), and parathyroid hormone receptors
(PTHR1, PTHR2).3,31 These 15 receptors share between 21 andThis journal is © The Royal Society of Chemistry 202067% sequence identity, and a large portion of the dissimilarity
is identied in the N-terminal sequence.31,35 These receptors
contain conserved cysteine residues in the rst and second
extracellular loops of the TMD regions (Fig. 3).31 However, the
majority of the receptors within this family contain conserved
cysteine residues that make up a cluster of cysteine bridges in
the N-terminus31 The binding prole of the secretin receptors is
outlined by three binding domains comprising of the proximal
region and the juxtamembrane region of the N-terminus, as well
as the extracellular loops, together with TM6 (Fig. 4).31 The
ligand is thought to activate the receptor by spanning the N-
terminal and the TMD extracellular loops, this way mediating
the active conformation of the receptor, which increases the
probability of activation of the signalling units.36RSC Adv., 2020, 10, 36337–36348 | 36339
Fig. 3 Illustration showing the modification of rhodopsin and its orientation in membranes.30 Reprinted with permission from Annual Reviews:
Annual Reviews, Annual review of biochemistry, G protein–coupled receptor rhodopsin, K. Palczewski, Copyright (2006). (a) Two-dimensional
illustration of rhodopsin. The polypeptide of rhodopsin is seen to cross the membrane seven times with C-I, C-II, C-III comparable to the
cytoplasmic loops and E-I, E-II, E-III to the extracellular loops. The yellow cylinders represent the transmembrane region (b) depicts the location
of the chromophore and the charges on the extracellular and cytoplasmic surface of rhodopsin. Red and blue colours represent negative and


































































































View Article OnlineIn addition to the presence of an extracellular N-terminal
domain (ECD) of 120–160 residues, three intracellular (IL) and
extracellular (EL) loops interconnect seven TMD (TM1-TM7) of
310–420 residues that are structurally similar and are thus
members of the family B GPCR.37,38 According to Parthier et al.36340 | RSC Adv., 2020, 10, 36337–36348hormonal recognition in family B GPCRs is believed to follow
the ‘two-domain’ binding mode, the N- and C-terminal regions
of the peptides interact with the J- and N-domains of the
receptors respectively, i.e. the C terminus of the peptide initiates
a peptide recognition with the ECD, thus allowing the peptide NThis journal is © The Royal Society of Chemistry 2020
Fig. 4 Schematic diagram showing the structure of family B GPCRs generated using ClustalW.31 Reprintedwith permission from Springer Nature:
Springer Nature, Nature Reviews Drug Discovery, Structural diversity of G protein-coupled receptors and significance for drug discovery, M. C.
Lagerström and H. B. Schiöth, Copyright (2008). The residues conserved in all 15 sequences are displayed as circles, the conserved polar residues
are shown in orange, the aromatic residues in purple, the aliphatic residues in beige, the positively and negatively charged residues are shown in
red and blue respectively.31 The uppercase letters show the completely conversed positions, the lowercase letters show the well-conserved
positions (>50%) while the letter “x” show the variable positions. The conserved sequence motifs which are found in the TMD of the family B
GPCRs are surrounded by red boxes.31 The conserved cysteine residues are depicted as yellow circles, the cysteine bridges between EL1 and EL2


































































































View Article Onlineterminus to bind the TMD ligand-binding pocket activating the
receptor and prompting a downstream signalling cascade.34,38–40
The presence of a conserved ECD structure and the ‘two-
domain’ binding mode across the family B GPCRs suggest
a similar receptor activation across the GPCR family.38
The secretin receptors have immense potential in drug
discovery due to their importance in fundamental homeostatic
functions.31,38 To date, three of these hormones (glucagon,
parathyroid hormone and calcitonin) are used clinically for the
treatment of hypoglycaemia, osteoporosis and hypercalcaemiaThis journal is © The Royal Society of Chemistry 2020individually.31 GLP1-R and GLP2-R are particularly relevant
targets, as a result of their part in appetite control and the
treatment of type 2 diabetes.31Family C (metabotropic glutamate
receptors)
The family C GPCRs comprise of the two g-aminobutyric acidB
receptors (GABAB receptors), odorant receptors in sh, eight


































































































View Article Onlinepheromone receptors, Ca2+-sensing receptors (CaS receptors or
CASR), sweet and umami taste receptors (TAS1R1-3), GPCR
Class C Group 6 Member A (GPRC6A) and seven orphan
receptors.3,4,31,41 The taste receptors in this GPCR family are
targeted by the taste additives used in the food industry.41 The
CaS, mGlu and GABAB receptors belong to a novel category of
drug targets that are essential for considering conditions which
affect the central nervous system and calcium homeostasis.42
Currently, family C GPCRs are targeted by two therapeutic drugs
in the market. One is Cinacalcet,41–45 the rst GPCR allosteric
modulator to be marketed, which targets the CaS receptor. The
other is Baclofen (now sold under the brand names Lioresal,
Liofen, Gablofen, etc.), which is a GABAB agonist used in the
treatment of muscle spasms.41,42,44–46Fig. 5 Graphical illustration of family C GPCR structure.41 Reprinted wit
logica Sinica, Structure and ligand recognition of class C GPCRs, L. Chu
nisation of family C GPCRs. Family C GPCRs have a peculiar structure whi
pocket, a CRD and a TMD except for GABAB receptor. (B) Graphical illust
and mGlu receptor (homodimer). There is a direct link between VFT and T
make an obligatory heterodimer while the VFT connects to TMD using CR
can potentially offer two other orthosteric binding pocket per dimer.41
36342 | RSC Adv., 2020, 10, 36337–36348The family C GPCRs differ from others by possessing a large
extracellular domain, distal to the TMD receptors, and con-
taining the orthosteric sites; they also form constitutive dimers
with unique activation systems in comparison with other GPCR
families.41 Similarly, to their related families, family C GPCRs
exhibit a typical motif of seven TMD helices however differ
structurally from other GPCR families in their possession of an
unusually large extracellular domain, an intracellular carboxyl-
terminal (C-terminal) domain and a heptahelical TMD
(Fig. 5A).41 The family C GPCRs are structurally distinct from
other GPCR families as a result of their extracellular domain
including a cysteine rich domain (CRD, with the exception of
GABAB receptor) and Venus ytrap module (VFT).31,41 The TM
domain of family C GPCRs contain only the allosteric bindingh permission from Springer Nature: Springer Nature, Acta Pharmaco-
n, W.-h. Zhang and J.-f. Liu (2012). (A) Represents the structural orga-
ch comprises of VFT with two lobes separated by an orthosteric binding
ration of two members family C GPCRs; GABAB receptor (heterodimer)
MD in the GABAB receptors and the two subunits, GABAB1 and GABAB2
D in the mGlu receptors. The mGlu receptors form homodimers which
This journal is © The Royal Society of Chemistry 2020
Table 1 Table showing some characteristics of family A–C GPCRsa
Feature Family A Family B Family C Reference
Transmembrane
domains
All families possess seven
transmembrane domains
31, 54 and 55
Orthosteric binding
site










33 16 22 57
Motifs All GPCRs share the
D/E-R-Y/W motifs




25 33 94 55
Type of ligand Small molecules, proteins,
peptides





Yes, except the sensory
receptors
Yes Yes, except the sensory receptors 31


































































































View Article Onlinesites differing from other families with their TM domains
conserved while the orthosteric sites are situated in the VFT
module.41,44 Domains present in the family C GPCRs provide
numerous ligand sites of action, bar the intracellular C-terminal
domain; this is highly variable and plays an essential role in
signalling protein coupling and scaffolding.41 The family C
GPCRs are unique due to their compulsory dimerization, either
as heterodimers (GABAB receptor and TIRs) or homodimers
(mGlu and CaS receptors) (Fig. 5B).41,47,48Structural differences
GPCRs share a common structural characteristic, the TMD
region, with its intracellular C-terminus and extracellular N-
terminus, which exhibits the greatest homology.21,28,49,50 The
intracellular loops which span TM5 and 6, the amino terminus
and the carboxyl terminus are among the most irregular struc-
tures in GPCRs with a substantial variation observed in the
amino terminus (N-terminus).21,51 The sequence is relatively
short for peptide and monoamine receptors comprising of
about 10–50 amino acids,21,51 and larger for glutamate family
receptors and glycoprotein hormone receptors (350–600 amino
acids).21,51 The largest amino terminal domains were observed
in the adhesion family receptors.21,51
Bortolato et al. compared crystal structures of family B and
family A GPCRs using receptors in the various classes (glucagon
receptors, corticotropin-releasing factor receptor 1 (CRF1) and
dopamine D3 receptor).52 The comparison of the CRF1 and
glucagon receptor crystal structure to dopamine D3 receptor,
a family A GPCR, showed that their cytoplasmic regions
superimposed well.52 However, the TM6 regions of both
glucagon receptors and CRF1 extend outwardly while the cyto-
plasmic moieties are situated in proximity to the TM3 regions in
sites similar to the dopamine, as well as other class A recep-
tors.52 The family B GPCRs lack the direct connectivity betweenThis journal is © The Royal Society of Chemistry 2020TM3 and TM6 which is regarded as the classical ‘ionic lock’,
playing an important role in family A GPCR activation.52,53 The
family C GPCRs structurally differ from family A and B due to
their remarkably large extracellular domain which comprises of
a cysteine-rich domain and VFT; an intracellular carboxyl-
terminal (C-terminal) domain. The TMD regions in family A
and B GPCRs are conserved however family C GPCRs have the
allosteric binding site within the TMD region (Fig. 4).41 Table 1
shows some of the characteristics of the GPCR families dis-
cussed in this review.Allosteric binding and cooperativity
Allostery is a widespread biological process, which is dened as
the ability of interactions occurring at a particular site on
a molecule to modulate actions on a different binding site on
the same molecule.58,59 For example, the binding of an allosteric
modulator on a molecule allosterically changes the conforma-
tion of its binding pocket as shown in Fig. 6. Currently, there are
two types of marketed pharmaceuticals: allosteric modulators,
which bind at the allosteric binding site on the receptor and
allosterically change the structural conformation of the receptor
binding site, and orthosteric modulators, which bind at the
active site of the receptor.60 Orthosterically-binding drugs must
overcome a major challenge in mediating the potential side
effects arising from binding to homologous proteins sharing
similar binding sites.60 Hence an orthosterically-binding drug
must have a very high affinity for its target, in order for a small
dose to selectively achieve the goal of target-only binding.60 The
binding of transcription factors (TFs) to DNA regulatory
elements (REs) provides a good example illustrating the speci-
city in orthosteric drugs.60
The process of GPCR signaling initiates when an endoge-
nous extracellular signal interacts with the orthosteric binding
site of a GPCR, resulting in a conformational change whichRSC Adv., 2020, 10, 36337–36348 | 36343
Fig. 6 Mechanism of action of allosteric modulators.63 Reprinted with permission from Springer Nature: Springer Nature, Nature Reviews Drug
Discovery, Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders, P. J. Conn, A. Christopoulos and C. W. Lindsley,
Copyright (2009). (a) Allosteric ligands bind to an alternative binding site on a receptor to modulate the activities of an orthosteric ligand efficacy
(blue) and/or affinity (red). A number of allosteric ligands can also directly disrupt signalling in their own right (green). (b) Results from simulation
show the effects on the function (right) or binding (left) of an orthosteric agonist mediated by three allosteric potentiators depicted in red, blue
and green; red enhanced orthosteric agonist affinity only, blue enhanced only the efficacy, green was observed to modestly enhance both


































































































View Article Onlinepasses on the signal through the plasma membrane traversing
the TMD region, and eventually activating intracellular
signaling cascades through heterotrimeric G proteins and other
adjunct proteins.58,61,62 A different approach, demonstrated for
ligand-gated particle channels, is the advancement of allosteric
modulators of the receptor subtypes, these small molecules do
not bind to the traditional orthosteric binding site, instead
interacting with the allosteric binding site to either enhance or
inhibit receptor activation.63
Allosteric GPCRmodulators show at least one of the outlined
pharmacological properties (Fig. 6). Agonism/reverse agonism:36344 | RSC Adv., 2020, 10, 36337–36348the allosteric modulator disrupts receptor signaling in either
a positive (agonism) or negative (antagonism) manner,
notwithstanding the presence or absence of an orthosteric
ligand.63 Efficacy modulation: the effect of allosterism causes
changes in intracellular responses, leading to alterations in the
inherent efficacy of an orthosteric ligand.63 Affinity modulation:
conformational change inuences the orthosteric binding
pocket, resulting in dissociation or association rate (or some-
times both) of the ligand being modied (Fig. 6).63 Some known
allosteric modulators of family B GPCRs include NovoNordisk
compounds 1–6:63 T-0632, which blocks the GLP-1 inducedThis journal is © The Royal Society of Chemistry 2020
Table 2 Some rules for the definition of dielectric constants in proteins
Denition Value Comments
Polar ¼ 3 large 3 ¼ large Protein sites are always polar near small radii
ions.Nonpolar ¼ 3 small
3ðrÞ ¼ 332Q1Q2
rDG






3B > 10 Proteins can provide as much solvation as water
for ionised groups with small radii.
3ðrÞ ¼ 332Q1m2 cos q
r2DG
3 $ 4 For functionally important charge–dipole
interactions, the value of 3 could be as small as
4. Such a low value, however, requires relatively



































































































View Article OnlinecAMP production63,64 (GLP 1 receptor); DMP696, which blocks
the CRF-stimulated adenylyl cyclase activity in cell line
expressing CRF1 receptor;63,65 NBI 27914, which blocks the CRF1
receptor;63,66 NBI 35965;63 antarlamin63 (CRF 1 receptor).63
Cooperativity is a thermodynamic term which has varying
meanings in different biochemical contexts.67,68 It is used to
explain the complex interactions of identical ligands with
a receptor at multiple binding sites.67 Cooperativity also
describes the thermodynamics of macromolecular conforma-
tional transitions, which include nucleic acid helix–coil transi-
tions and protein folding.67 Positive cooperativity is dened as
the increase of binding affinity at one site of a receptor when
a ligand is bound elsewhere.69 A classic example of positive
cooperativity is the binding of oxygen to haemoglobin; the
binding of one oxygen molecule to the ferrous iron of the heme
molecule increases the affinity of deoxyhaemoglobin for
oxygen.69 Negative cooperativity is observed when 2,3-bisphos-
phoglycerate binds to an allosteric binding site of haemoglobin
and the affinity for oxygen is reduced.67,69GPCR signalling via G-proteins
G-proteins consist of several families of varied cellular proteins
which perform several cellular functions, such as contractility
and angiogenesis, learning and memory.70,71 These proteins
bind to the guanine nucleotides (guanine diphosphate (GDP)
and guanine triphosphate (GTP)) and also have inherent
GTPase activity.71 They play a principal role in a many cellular
processes, including protein synthesis and cell development,
vesicular transport, and cytoskeleton assembly, in addition to
signal transduction.71 G-proteins are trimers comprising of two
functional components: a beta-gamma dimer (35 and 8 kDa)
which closely relates with the alpha subunit upon binding with
GDP, and an alpha subunit (39–52 kDa) which is a catalyst for
GTPase activity.72 Human G proteins are classied into two
classes, namely small (monomeric), and heterotrimeric G
proteins.71,72
GPCRs are the largest superfamily of cell-surface receptors
involved in TMD signalling, usually transmitting signals into
cells via their response to a range of extracellular stimuli, such
as glycoproteins, polypeptides and ions, and hence regulatingThis journal is © The Royal Society of Chemistry 2020a wide variety of physiological and developmental functions.73
The intracellular-signalling cascades activated by GPCRs have
been proven to be remarkably complex.73,74 The binding of
a ligand to the GPCR binding site leads to a conformational
change in the receptor, in turn promoting the binding of the
heterotrimeric G proteins, consisting of Ga-GDP and Gbg-
subunits, within the intracellular moiety of the receptor.74 The
exchange of GTP for GDP on the Ga-subunit results in the
reversible dissociation of the G protein subunits, initiating
a downstream signalling via Ga-GTP and Gbg.73,74Dielectric constant
The most effective way of correlating the structure and function
of macromolecules is through the examination of its electro-
static energies.75 The intermolecular interactions present are
affected by the effective dielectric constant (relative permittivity,
3r),76 which differs according to the size and composition of the
protein.77 The accuracy of the method of determination is
important in understanding various biochemical interactions
such as protein–ligand and protein–protein interactions, charge
separation, ion channel selectivity and electron and proton
transfer signal transduction and macromolecular assembly;77,78
these interactions are inuenced by the electrostatic potential
of the protein surface.77–79 The dielectric constant of dry
proteins ranges from 2.5 to 3.5 obtained from direct measure-
ment.78 The theoretical calculation of local dielectric constant of
lone proteins based on their amino acid composition yielded an
average of 2.7.80 The polarity of the residues which make up the
structural motifs within a protein have been shown to affect its
dielectric constant values, these ndings were based on
computational studies based on continuum electrostatics and
molecular dynamics simulations.77,78
According to Warshel and Åqvist, the value of the dielectric
constant of proteins is dependent on the property used to dene
it. They highlighted several possible ways of dening the
dielectric constant in proteins, as outlined in Table 2,81 where
Q1 andQ2 are charges on ionisable groups separated by distance
r, m is a group dipole moment (in units of electron Ångström),


































































































View Article Onlineof charge, and 3B is the effective dielectric constant associated
with a given interaction.
Li et al. reported that the average dielectric constant inside
a protein is relatively low, about 6–7, but this gure reaches
about 20–30 on the surface of the protein.82 The high average
local dielectric constant values are oen linked to the charged
residues while the low values are assigned automatically to the
regions comprised of mostly hydrophobic residues.82
According to Wilson et al. solvent effects on mechanisms of
reactions have been established, but its effect on kinetic isotope
effects (KIEs) are rather well less comprehended.83 A change in
solvent can alter the KIE indirectly by changing the transition-
state (TS) structure. It can also affect KIE by affecting isotopi-
cally sensitive vibrational frequencies directly, notwithstanding
the TS structure or identity of the rate-determining step.83 Wilson
et al. investigated the medium effects on KIE for SN2 methyl
transfer using UFF or UAO cavity method within the polarized
continuum model (PCM) and a hybrid quantum mechanical/
molecular mechanical (QM/MM) method.83 Their ndings
showed that the majority of variation in the equilibrium isotope
effects (EIE) occur within the same range of dielectric constants
(1# 3# 10) as is considered to occur with enzyme active sites and
proteins.83 There is a possibility that any reaction which involves
separation, neutralisation or charge distribution within an
enzyme active site could indicate variations in KIEs, between
a wildtype and mutant form of an enzyme, which originates as
a result of changes in the local dielectric response within the
diverse protein environment.83 The use of UFF or UAO cavity
method within the polarized continuum model (PCM) and
a hybrid QM/MM method to characterise ligand binding in
GPCRs would further assist in understanding the interactions
which occur in the both the active and inactive states of GPCRs,
as well the changes which occur during the transition from
inactive state to active state upon ligand activation.Computational biology techniques in
GPCR research
The rst major breakthrough in human GPCR structural
biology took place in 2007 as the solving of the b2-adrenergic
receptor (b2AR with a diffusible ligand) using a modied lipidic
cubic phase (LCP) produce to produce b2AR-TCL crystals which
diffracted to a resolution of 2.2 Å, the structure was further
rened at a 2.4 Å resolution.12 Presently 64 structures of unique
GPCRs with varying resolutions have been solved using spec-
troscopic methods such as uorescence, electron paramagnetic
resonance (EPR) and nuclear magnetic resonance (NMR) spec-
troscopy and structural techniques such as cryogenic electron
microscopy (cryo-EM), this provides opportunities in employing
computational biology techniques such as molecular model-
ling, and molecular docking in drug discovery research.84,85 The
milestones achieved in GPCR structural studies have provided
insights on the arrangements of the transmembrane
domains,1–5,11,12 the location of the orthosteric,12,31,41 allo-
steric,12,31,41 bitopic,12 as well as biased ligand binding sites,12
the homo- or hetero-oligomerization of receptors12 and the36346 | RSC Adv., 2020, 10, 36337–36348structural rearrangements associated with conformational
changes upon GPCR activation and inactivation.12 This base of
structural information on GPCRs is vital for SBDD,12,86 ligand-
based drug design (LBDD),12 and integrated models which
complement drug discovery efforts.12
In 2012, Sosei Heptares published a detailed account on the
use of A2AR structure in identifying series of agents as potential
antagonists, this became the rst published GPCR SBDD
discovery.87 In a research carried out by de Graaf et al. using
structure based virtual screening (SBVS), they identied allo-
steric modulators of two family B receptors namely; glucagon
receptor and glucagon-like peptide receptor.88 SBDD
approaches has also lead to the development of new agonists of
the A3 adenosine receptor (A3AR).89
Conclusion and future prospects
GPCRs are multifaceted proteins which exist in varying
conformations, and that the conformational equilibrium of
these group of receptors is inuenced both by the bound ligand
and the proximity to the related G protein. Their structure is
highly conserved comprising of seven TMD. These receptors
possess different binding domains, namely; allosteric and
orthosteric binding domains. The progress in GPCR structural
biology has substantially accelerated our understanding of
GPCRs as potential drug targets using SBDD and LBDD
approaches. Further computational studies assessing nuclear
quantum effects on ligand receptor binding, as well as hybrid
QM/MM and empirical valence bond theory in the mechanistic
studies of GPCRs would allow for further insight into the
interactions which occur in both the active and inactive states of
GPCRs, as well the changes which occur during the transition
from these states upon ligand activation. This review has aimed
to provide an accessible and introductory perspective on
advances in GPCR-based drug discovery approaches; many
reviews on the topic highlighted herein are indeed highly
detailed and authoritative but may not provide as accessible an
account for a less specialised or more general audience in the
chemical sciences.
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